8-KOther Events

JOHNSON & JOHNSON 8-K Report, Corporate Update (Jan 18, 2005)

Filed January 18, 2005For Securities:JNJ

Summary

This Form 8-K filing by Johnson & Johnson (JNJ) on January 18, 2005, announces a significant executive leadership change. Christine A. Poon has been appointed Vice Chairman of Johnson & Johnson, a newly created role. This appointment reflects her growing influence and responsibility within the company. Furthermore, Ms. Poon has been nominated for election to the Board of Directors at the upcoming April 2005 Annual Meeting of Shareholders. She will continue to oversee all pharmaceutical, consumer pharmaceutical, and nutritional businesses, reporting directly to Mr. Weldon. Investors should view this as a positive development, indicating a strong succession plan and the elevation of experienced leadership to key strategic positions within the organization.

Key Highlights

  • 1Christine A. Poon appointed Vice Chairman of Johnson & Johnson.
  • 2Ms. Poon nominated for election to the Board of Directors at the April 2005 Annual Meeting.
  • 3Ms. Poon retains management responsibility for pharmaceutical, consumer pharmaceutical, and nutritional businesses.
  • 4Ms. Poon will report directly to Mr. Weldon in her new role.
  • 5This appointment is effective as of January 12, 2005.
  • 6Ms. Poon has a strong background in the pharmaceutical industry, including prior roles at Bristol-Myers Squibb.

Frequently Asked Questions

Christine A. Poon's appointment as Vice Chairman signifies a promotion to a senior leadership role. It indicates her importance to the company's strategic direction and highlights a strong succession plan. She will continue to manage key business segments, showing continued trust in her leadership.

Yes, Ms. Poon has been nominated by the Nominating & Corporate Governance Committee for election to the Board of Directors at Johnson & Johnson's Annual Meeting of Shareholders in April 2005. Her potential addition to the board underscores her significant contributions and influence within the company.

Ms. Poon will continue to have full management responsibility for all of Johnson & Johnson's pharmaceutical, consumer pharmaceutical, and nutritional businesses. This demonstrates that her expanded role as Vice Chairman will not diminish her operational oversight of these crucial divisions.

Ms. Poon, age 52 at the time of the filing, has extensive experience in the pharmaceutical sector. She joined Johnson & Johnson in 2000 and previously held roles as Worldwide Chairman of Medicines and Nutritionals (2003), Worldwide Chairman of Pharmaceuticals (2001), and Company Group Chairman of Pharmaceuticals. Prior to joining JNJ, she had a 15-year career at Bristol-Myers Squibb, where she held various senior management positions, including President of International Medicines.